Nonstimulants are also recommended for those that do not see the full benefit from stimulant medications...Vviloxazine (Qelbree), is a new treatment option, approved in the United States in April 2021. This drug is a norepinephrine reuptake inhibitor indicated for patients aged 6 to 17 years.